| # | Drug | Count |
|---|---|---|
| 0 | OCRELIZUMAB | 509 |
| 1 | RITUXIMAB | 421 |
| 2 | CYCLOPHOSPHAMIDE | 130 |
| 3 | CYCLOPHOSPHAMIDE FOR INJECTION | 130 |
| 4 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 130 |
| 5 | DALFAMPRIDINE | 115 |
| 6 | OFATUMUMAB | 96 |
| 7 | PREDNISONE | 94 |
| 8 | METHYLPREDNISOLONE | 84 |
| 9 | MYCOPHENOLATE MOFETIL | 84 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | OCRELIZUMAB | 509 | 0.0081 |
| 1 | CLEMASTINE FUMARATE | 7 | 0.0050 |
| 2 | BARICITINIB | 14 | 0.0046 |
| 3 | EPINASTINE HYDROCHLORIDE | 5 | 0.0044 |
| 4 | UBLITUXIMAB | 15 | 0.0039 |
| 5 | ESTRIOL | 6 | 0.0033 |
| 6 | VINBLASTINE SULFATE | 6 | 0.0031 |
| 7 | OFATUMUMAB | 96 | 0.0029 |
| 8 | SATRALIZUMAB | 5 | 0.0028 |
| 9 | ERGOCALCIFEROL | 65 | 0.0022 |
| # | Drug class | Count |
|---|---|---|
| 0 | CD20-directed Cytolytic Antibody [EPC] | 1009 |
| 1 | Corticosteroid [EPC] | 308 |
| 2 | Nonsteroidal Anti-inflammatory Drug [EPC] | 146 |
| 3 | Alkylating Drug [EPC] | 136 |
| 4 | Potassium Channel Blocker [EPC] | 115 |
| 5 | gamma-Aminobutyric Acid-ergic Agonist [EPC] | 72 |
| 6 | Purine Antimetabolite [EPC] | 69 |
| 7 | Provitamin D2 Compound [EPC] | 65 |
| 8 | Vitamin C [EPC] | 48 |
| 9 | Vitamin B12 [EPC] | 46 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CD19-directed Cytolytic Antibody [EPC] | 4 | 0.0047 |
| 1 | CD20-directed Cytolytic Antibody [EPC] | 1009 | 0.0032 |
| 2 | Provitamin D2 Compound [EPC] | 65 | 0.0022 |
| 3 | CD38-directed Cytolytic Antibody [EPC] | 12 | 0.0021 |
| 4 | CD52-directed Cytolytic Antibody [EPC] | 35 | 0.0018 |
| 5 | Potassium Channel Blocker [EPC] | 115 | 0.0016 |
| 6 | Cannabinoid [EPC] | 13 | 0.0016 |
| 7 | Human Immunoglobulin G [EPC] | 28 | 0.0013 |
| 8 | Adrenocorticotropic Hormone [EPC] | 1 | 0.0011 |
| 9 | Endoglycosidase [EPC] | 2 | 0.0011 |